Colin Ng - Founder & CEO - GREATER BAY BIOTECHNOLOGY LIMITED

Colin Ng is the Founder and CEO of Greater Bay Biotechnology (GBBT), which focuses on the research, development and commercialisation of transdermal drug and cell delivery technology with wide applications including the treatment of diseases (e.g. diabetes, cancer) and anti-aging. GBBT is a business supported by CityU HK Tech 300 Seed and Angel funds, HKSTP Ideation and HKSAR Government ITF’s Technology Start-up Support Scheme for Universities (TSSSU). Colin has led GBBT to win numerous domestic and international awards and is growing in HK and Mainland.

Prior to his current position, Colin has worked in senior roles at Global 500 enterprises including EY, ANZ Bank, Standard Chartered, Prudential and he has advised major investors in the biotechnology and pharmaceutical sectors on strategy, corporate development, incubation and IPO. Colin has four masters degrees: MSc in Health Sciences and Management from CityU, a MSc (Real Estate) from University of Hong Kong, a Master of Applied Finance and Investment from Securities Institute of Australia, a MBA from University of New South Wales & University of Sydney, and a Bachelor of Commerce (Accounting) from University of New South Wales. Colin is a Fellow (FCPA) of Hong Kong Institute of Certified Public Accountants, a Chartered Accountant (CA) of Chartered Accountants Australia & New Zealand.